Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor

por Fujino, Toshio, Mitsudomi, Tetsuya
Publicado 2021

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges

por Fujino, Toshio, Suda, Kenichi, Mitsudomi, Tetsuya
Publicado 2021

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors

por Soh, Junichi, Hamada, Akira, Fujino, Toshio, Mitsudomi, Tetsuya
Publicado 2021

A new approach to left sleeve pneumonectomy: complete VATS left pneumonectomy followed by right thoracotomy for carinal resection and reconstruction

por Fujino, Toshio, Tanahashi, Masayuki, Yukiue, Haruhiro, Suzuki, Eriko, Yoshii, Naoko, Shitara, Masayuki, Kaminuma, Yasunori, Niwa, Hiroshi
Publicado 2018

Micronodular thymoma with lymphoid stroma diagnosed 10 years after the first operation: a case report

por Kaminuma, Yasunori, Tanahashi, Masayuki, Yukiue, Haruhiro, Suzuki, Eriko, Yoshii, Naoko, Fujino, Toshio, Ogawa, Hiroshi, Niwa, Hiroshi
Publicado 2019

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

por Fujino, Toshio, Suda, Kenichi, Koga, Takamasa, Hamada, Akira, Ohara, Shuta, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Soh, Junichi, Mitsudomi, Tetsuya
Publicado 2022

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance

por Nishino, Masaya, Suda, Kenichi, Koga, Takamasa, Ohara, Shuta, Fujino, Toshio, Soh, Junichi, Tirunagaru, Vijaya, Vellanki, Avanish, Doebele, Robert C., Mitsudomi, Tetsuya
Publicado 2021

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study

por Koga, Takamasa, Suda, Kenichi, Nishino, Masaya, Fujino, Toshio, Ohara, Shuta, Hamada, Akira, Soh, Junichi, Tirunagaru, Vijaya, Vellanki, Avanish, Doebele, Robert C., Mitsudomi, Tetsuya
Publicado 2021

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer

por Lim, Sun Min, Fujino, Toshio, Kim, Chulwon, Lee, Gwanghee, Lee, Yong-Hee, Kim, Dong-Wan, Ahn, Jin Seok, Mitsudomi, Tetsuya, Jin, Taiguang, Lee, Sang-Yoon
Publicado 2023

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study

por Ohara, Shuta, Suda, Kenichi, Sakai, Kazuko, Nishino, Masaya, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Fujino, Toshio, Koga, Takamasa, Hamada, Akira, Soh, Junichi, Nishio, Kazuto, Mitsudomi, Tetsuya
Publicado 2020

Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing

por Koga, Takamasa, Soh, Junichi, Hamada, Akira, Miyano, Yuki, Fujino, Toshio, Obata, Keiko, Ohara, Shuta, Nishino, Masaya, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Suda, Kenichi, Sakai, Kazuko, Sato, Hidenori, Mitsudomi, Tetsuya
Publicado 2023

Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis

por Ohara, Shuta, Tomizawa, Kenji, Shimizu, Shigeki, Suda, Kenichi, Fujino, Toshio, Hamada, Akira, Koga, Takamasa, Nishino, Masaya, Kobayashi, Yoshihisa, Sato, Katsuaki, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Soh, Junichi, Mitsudomi, Tetsuya
Publicado 2019

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC

por Hamada, Akira, Suda, Kenichi, Fujino, Toshio, Nishino, Masaya, Ohara, Shuta, Koga, Takamasa, Kabasawa, Takanobu, Chiba, Masato, Shimoji, Masaki, Endoh, Makoto, Takemoto, Toshiki, Soh, Junichi, Yanagawa, Naoki, Shiono, Satoshi, Mitsudomi, Tetsuya
Publicado 2022